103 related articles for article (PubMed ID: 7741767)
1. Site of action of two novel pyrimidine biosynthesis inhibitors accurately predicted by the compare program.
Cleaveland ES; Monks A; Vaigro-Wolff A; Zaharevitz DW; Paull K; Ardalan K; Cooney DA; Ford H
Biochem Pharmacol; 1995 Mar; 49(7):947-54. PubMed ID: 7741767
[TBL] [Abstract][Full Text] [Related]
2. Redoxal as a new lead structure for dihydroorotate dehydrogenase inhibitors: a kinetic study of the inhibition mechanism.
Knecht W; Löffler M
FEBS Lett; 2000 Feb; 467(1):27-30. PubMed ID: 10664450
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel inhibitor (NSC 665564) of dihydroorotate dehydrogenase with a potency equivalent to brequinar.
Cleaveland ES; Zaharevitz DW; Kelley JA; Paull K; Cooney DA; Ford H
Biochem Biophys Res Commun; 1996 Jun; 223(3):654-9. PubMed ID: 8687451
[TBL] [Abstract][Full Text] [Related]
4. Antipyrimidine effects of five different pyrimidine de novo synthesis inhibitors in three head and neck cancer cell lines.
Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2018; 37(6):329-339. PubMed ID: 29723133
[TBL] [Abstract][Full Text] [Related]
5. Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid.
Knecht W; Henseling J; Löffler M
Chem Biol Interact; 2000 Jan; 124(1):61-76. PubMed ID: 10658902
[TBL] [Abstract][Full Text] [Related]
6. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.
Rückemann K; Fairbanks LD; Carrey EA; Hawrylowicz CM; Richards DF; Kirschbaum B; Simmonds HA
J Biol Chem; 1998 Aug; 273(34):21682-91. PubMed ID: 9705303
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium.
Chen SF; Perrella FW; Behrens DL; Papp LM
Cancer Res; 1992 Jul; 52(13):3521-7. PubMed ID: 1617622
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic effects of inhibitors of de novo pyrimidine biosynthesis upon Plasmodium falciparum.
Seymour KK; Lyons SD; Phillips L; Rieckmann KH; Christopherson RI
Biochemistry; 1994 May; 33(17):5268-74. PubMed ID: 7909690
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390).
Peters GJ; Sharma SL; Laurensse E; Pinedo HM
Invest New Drugs; 1987; 5(3):235-44. PubMed ID: 2822596
[TBL] [Abstract][Full Text] [Related]
10. Effects of acivicin and dichloroallyl lawsone upon pyrimidine biosynthesis in mouse L1210 leukemia cells.
Kemp AJ; Lyons SD; Christopherson RI
J Biol Chem; 1986 Nov; 261(32):14891-5. PubMed ID: 3771555
[TBL] [Abstract][Full Text] [Related]
11. Malarial dihydroorotate dehydrogenase. Substrate and inhibitor specificity.
Baldwin J; Farajallah AM; Malmquist NA; Rathod PK; Phillips MA
J Biol Chem; 2002 Nov; 277(44):41827-34. PubMed ID: 12189151
[TBL] [Abstract][Full Text] [Related]
12. DUP 785 (NSC 368390): schedule-dependency of growth-inhibitory and antipyrimidine effects.
Schwartsmann G; Peters GJ; Laurensse E; de Waal FC; Loonen AH; Leyva A; Pinedo HM
Biochem Pharmacol; 1988 Sep; 37(17):3257-66. PubMed ID: 2840910
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of resistance to cyclopentenyl cytosine (CPE-C) in Molt-4 lymphoblasts.
Blaney SM; Grem JL; Balis FM; Cole DE; Adamson PC; Poplack DG
Biochem Pharmacol; 1993 Apr; 45(7):1493-501. PubMed ID: 8471071
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis.
He T; Haapa-Paananen S; Kaminskyy VO; Kohonen P; Fey V; Zhivotovsky B; Kallioniemi O; Perälä M
Oncogene; 2014 Jul; 33(27):3538-49. PubMed ID: 24013224
[TBL] [Abstract][Full Text] [Related]
15. Effects of brequinar and ciprofloxacin on de novo nucleotide biosynthesis in mouse L1210 leukemia.
Lyons SD; Christopherson RI
Biochem Int; 1990 Dec; 22(6):939-49. PubMed ID: 1965281
[TBL] [Abstract][Full Text] [Related]
16. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives.
Knecht W; Löffler M
Biochem Pharmacol; 1998 Nov; 56(9):1259-64. PubMed ID: 9802339
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationship of quinoline carboxylic acids. A new class of inhibitors of dihydroorotate dehydrogenase.
Chen SF; Papp LM; Ardecky RJ; Rao GV; Hesson DP; Forbes M; Dexter DL
Biochem Pharmacol; 1990 Aug; 40(4):709-14. PubMed ID: 2386542
[TBL] [Abstract][Full Text] [Related]
18. Pyrimidine nucleoside depletion sensitizes to the mitochondrial hepatotoxicity of the reverse transcriptase inhibitor stavudine.
Setzer B; Lebrecht D; Walker UA
Am J Pathol; 2008 Mar; 172(3):681-90. PubMed ID: 18276780
[TBL] [Abstract][Full Text] [Related]
19. The "anti-pyrimidine effect" of hypoxia and brequinar sodium (NSC 368390) is of consequence for tumor cell growth.
Löffler M
Biochem Pharmacol; 1992 May; 43(10):2281-7. PubMed ID: 1599514
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of action of the novel anticancer agent 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarbo xylic acid sodium salt (NSC 368390): inhibition of de novo pyrimidine nucleotide biosynthesis.
Chen SF; Ruben RL; Dexter DL
Cancer Res; 1986 Oct; 46(10):5014-9. PubMed ID: 3019518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]